INTRODUCTION
============

Polyunsaturated fatty acids (PUFAs) in membrane phospholipids play critical roles in regulating the structure, dynamics, and permeability of membranes. In mammals, the PUFA composition affects many cellular processes, including modulation of ion channels ([@B12]; [@B60]) and activities of membrane-associated enzymes that are sensitive to the biophysical properties of lipid membrane ([@B23]). Postnatal PUFA depletion causes various abnormalities, including sterility, ulceration, and dermatitis, and PUFA supplementation can alleviate most of those symptoms ([@B51]; [@B52]; [@B42]; [@B59]). Arachidonic acid (AA; 20:4n-6) is the most enriched n-6 PUFA in the brain and is involved in multiple aspects of neuronal development and function, including neurite outgrowth, signal transduction, and membrane fluidity. The prenatal and postnatal status of AA is associated with early postnatal neurological function ([@B17]; [@B62]). There are several lines of evidence suggesting that AA has more beneficial effects than other n-6 fatty acids for perinatal infants. Human infants, as well as neonatal animals, have a reduced ability to elongate/desaturate fatty acids to an appropriate degree, and supplementation with linoleic acid and linolenic acid is not sufficient to overcome a PUFA-deficiency state ([@B1]). AA is preferentially transferred across the placenta compared with other n-6 fatty acids ([@B15]). Moreover, a neurological optimality score that quantifies the quality of neonatal neurological functioning is positively related with AA but not with other n-6 fatty acids ([@B17]). Nutritional studies also suggest that AA supplementation ameliorates cognitive function in aged animals ([@B29]; [@B38]) and helps to protect against a variety of mental disorders ([@B33]).

Among membrane phospholipids, phosphatidylinositol (PI) is unique in its fatty acid composition, that is, most of the fatty acid attached to the *sn-*2 position of PI is AA (20:4n-6), whereas other major membrane phospholipids such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE) contain various PUFAs, including docosahexaenoic acid (DHA; 22:6n-3; [@B28]; [@B40]; [@B35]; [@B53]). However, the physiological significance of the enrichment of AA in PI is unclear. AA-containing PI is formed by fatty acid remodeling after the de novo synthesis of PI through sequential deacylation and reacylation reactions ([@B25]; [@B4]; Luthra and Sheltawy, 1976). Although high levels of lysophosphatidylinositol acyltransferase (LPIAT) activities were detected from various mammalian tissues by in vitro assays ([@B4]; [@B27]; [@B44]; [@B61]), the gene responsible for the activity was not identified until recently. In an RNA interference--based genetic screen using *Caenorhabditis elegans*, we identified a gene encoding an acyltransferase that selectively incorporates AA into PI and named it *mboa-7* ([@B30]). We also showed that a human orthologue of *mboa-7* exhibited arachidonoyl-CoA (AA-CoA):LPIAT activity and that small interfering RNA--mediated knockdown selectively reduced the AA-CoA:LPIAT activity and \[^14^C\]AA incorporation into the PI fraction in HeLa cells. Voelker\'s group named a mammalian orthologue of *mboa-7* "MBOAT7" and showed that MBOAT7 is an LPIAT with remarkable specificity for AA-CoA by using mass spectrometry--based enzyme assays ([@B21]). *Drosophila* orthologue also prefers AA-CoA as an acyl donor ([@B50]). [@B48]) renamed MBOAT7 as LPIAT1 based on its substrate specificity and by the order of its publication in their review. In the present study, we generated LPIAT1-knockout mice to elucidate the physiological significance of AA in PI.

RESULTS
=======

Targeted deletion of the *Lpiat1* gene in the mouse
---------------------------------------------------

To determine the physiological role of LPIAT1 in mammals, we generated LPIAT1-deficient mice (*Lpiat1^−/−^* mice) by gene targeting ([Figure 1, A and B](#F1){ref-type="fig"}). A targeting vector substituted a neomycin-resistant gene for exons 2--4 of the *Lpiat1* gene, deleting the initiation codon. Western blot analysis of wild-type mice revealed high expression of LPIAT1 in the brain among the tissues tested ([Figure 1C](#F1){ref-type="fig"}). In the fetal brain, expression of LPIAT1 was observed in the cerebral cortex ([Figure 1D](#F1){ref-type="fig"}), the CA regions and the dentate gyrus of the hippocampus ([Figure 1E](#F1){ref-type="fig"}), the external plexiform layer and the mitral cell layer of the olfactory bulb ([Figure 1F](#F1){ref-type="fig"}), and the granular cell layer of the cerebellum ([Figure 1G](#F1){ref-type="fig"}). In contrast, LPIAT1 protein was not detected in tissues from *Lpiat1^−/−^* mice ([Figure 1, C--G](#F1){ref-type="fig"}). LPIAT activity with AA-CoA as an acyl donor was almost absent in the membranes of the brain ([Figure 1H](#F1){ref-type="fig"}), but acyltransferase activities toward other lysophospholipids were not changed ([Figure 1I](#F1){ref-type="fig"}). AA-CoA:LPIAT activity was also undetectable in the membranes of the liver, kidney, and testis from *Lpiat1^−/−^* mice ([Figure 1H](#F1){ref-type="fig"}). These data indicate that LPIAT1 is the predominant enzyme that catalyzes the incorporation of AA into lysoPI in mice.

![*Lpiat1^−/^*^−^ mice lack AA-CoA:LPIAT activity. (A) Diagram of the *Lpiat1* genomic locus and the targeting vector. The positions of the PCR primers (P1, P2, and P3) are indicated. All three primers were used in the same PCR. (B) PCR analysis of genomic DNAs from *Lpiat1*^+/+^, *Lpiat1*^+/−^, and *Lpiat1*^−/−^ mice. (C) Immunoblot analysis of LPIAT1. Each tissue was prepared from 2-wk-old *Lpiat1^+/+^* and *Lpiat1^−/−^* mice. Control GAPDH was run simultaneously in a different gel. The same amount of protein was loaded in each lane. (D--G) LPIAT1 expression in the brain. Sagittal sections of the brains from E18.5 *Lpiat1*^+/+^ and *Lpiat1*^−/−^ littermates were stained with antibodies against mouse LPIAT1. Neocortex (D), hippocampus (E), olfactory bulb (F), and cerebellum (G) are shown. LPIAT1 was also detected in granule cells in accessory olfactory bulb. Scale bar, 100 μm. (H) AA-CoA:LPIAT activity in the membrane fractions of each tissue from *Lpiat1*^+/+^, *Lpiat1*^+/−^, and *Lpiat1*^−/−^ mice at 2 wk of age. \[^14^C\]AA-CoA, lysoPI, and 5 μg of protein were used. Data are means ± SD (*n* = 3). (I) AA-CoA:lysophospholipid acyltransferase activity of the *Lpiat1*^+/+^, *Lpiat1*^+/−^, and *Lpiat1*^−/−^ brains using the indicated lysophospholipids as acyl acceptors. PS, phosphatidylserine; PA, phosphatidic acid. Protein at 20 μg was used. Data are means ± SD (*n* = 3).](4689fig1){#F1}

*Lpiat1*^−/−^ mice show reduced AA content in PI and PI phosphates
------------------------------------------------------------------

PI participates in various types of signal transduction through distinct phosphorylated derivatives of the inositol head group ([@B16]; [@B45]). Therefore we analyzed the fatty acyl species of PI and PI phosphates in the *Lpiat1^−/^*^−^ brain. The amount of AA in total PI fatty acids in the *Lpiat1^−/^*^−^ brain (28%) was significantly less than that in the *Lpiat1^+/+^* brain (43%; [Figure 2A](#F2){ref-type="fig"}). Conversely, other fatty acids, such as palmitic acid (16:0) and DHA in PI, were increased in the *Lpiat1^−/^*^−^ brain. Consistent with this observation, liquid chromatography--electrospray ionization mass spectrometry (LC/ESI-MS) analysis revealed that the amount of 18:0/20:4 PI (38:4 PI) was significantly reduced in the *Lpiat1^−/^*^−^ brain ([Figure 2, B and C](#F2){ref-type="fig"}). The molecular species compositions of PC and PE were not significantly affected ([Figure 2, D and E](#F2){ref-type="fig"}). PI content was slightly decreased in the *Lpiat1^−/^*^−^ brain ([Figure 2F](#F2){ref-type="fig"}). In addition to the reduced content of AA in PI, the fatty acyl species of PI monophosphate (PIP; primarily phosphatidylinositol 4-phosphate \[PI4P\]) and PI bisphosphate (PIP~2~; primarily phosphatidylinositol 4,5-bisphosphate \[PI(4,5)P~2~\]) were affected in a manner similar to that of PI ([Figure 2, G and H](#F2){ref-type="fig"}). The contents of PI phosphates in the *Lpiat1^+/+^* and *Lpiat1^−/^*^−^ brains could not be measured because the values fluctuated from experiment to experiment.

![Lipid analysis of *Lpiat1^−/^*^−^ mice. (A) Analysis of PI fatty acid composition of the brains by gas chromatography. C16:0, palmitic acid; C18:0, stearic acid; C18:1n-9, oleic acid; C18:1n-7, vaccenic acid; C20:4n-6, arachidonic acid; C22:4n-6, docosatetraenoic acid; C22:6n-3, docosahexaenoic acid. Data are means ± SEM (*n* = 3). \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. The unpaired, two-tailed *t* test was used. (B) LC-MS/MS analysis of PI. Negative-ionization LC-MS spectra of PI molecular species of the *Lpiat1^+/+^* and *Lpiat1^−/^*^−^ brains. 34:1, 16:0/18:1; 36:1, 18:0/18:1; 36:2, 18:1/18:1; 36:4, 16:0/20:4; 38:4, 18:0/20:4; 38:5, 18:1/20:4; 40:6, 18:0/22:6; 40:7, 18:1/22:6. Data are means ± SEM (*n* = 5). \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. The unpaired, two-tailed *t* test was used. (C) Negative-ionization LC-MS spectra of PI molecular species of the *Lpiat1*^+/+^ (top) and *Lpiat1*^−/−^ (bottom) brains. 36:4, 16:0/20:4; 38:4, 18:0/20:4; 40:6, 18:0/22:6. (D) Positive-ionization LC-MS spectra of PC molecular species. 32:1, mainly 16:0/16:1; 32:0, 16:0/16:0; 34:1, 16:0/18:1; 36:4, mainly 16:0/20:4; 36:1, 18:0/18:1; 38:6, 16:0/22:6; 38:4, mainly 18:0/20:4; 40:6, 18:0/22:6. (E) Positive-ionization LC-MS spectra of PE molecular species. 34:1, 16:0/18:1; 38:6 alkenyl, 16:0 alkenyl/22:6; 38:6, mainly 16:0/22:6; 38:4, mainly 18:0/20:4; 40:6 alkenyl, 18:0 alkenyl/22:6; 40:6, 18:0/22:6. (F) The content of individual phospholipid of the brains. Data are means ± SEM (*n* = 4-5). \**p* \< 0.05. The unpaired, two-tailed *t* test was used. (G, H) LC/MS analysis of PIP (primarily PI4P; G) and PIP~2~ (primarily PI(4,5)P~2~; H) of *Lpiat1*^+/+^ and *Lpiat1*^−/−^ mouse hippocampus. Data are means ± SEM (*n* = 3). \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Unpaired, two-tailed *t* test was used.](4689fig2){#F2}

As shown previously ([@B39]), acyltransferase activity with AA-CoA as an acyl donor toward lysoPI4P or lysoPI(4,5)P~2~ was almost undetectable in the membranes of the brain from wild-type mice compared with the activity toward lysoPI ([Figure 3A](#F3){ref-type="fig"}). Overexpression of LPIAT1 did not increase the acyltransferase activity toward lysoPI4P or lysoPI(4,5)P~2~ ([Figure 3B](#F3){ref-type="fig"}). These data indicate that AA-containing PI phosphates are not formed by incorporation of AA into lysoPI phosphates.

![LPIAT1 does not use lysoPI4P or lysoPI(4,5)P~2~ as acyl acceptors. (A) AA-CoA:acyltransferase activity toward lysoPI, lysoPI4P, or lysoPI(4,5)P~2~ in the membrane fractions of the *Lpiat1*^+/+^ and *Lpiat1*^−/−^ brains at P0. Protein at 5 μg was used. ND, not detected or present only in trace amounts. Data are means ± SD (*n* = 3). (B) AA-CoA:acyltransferase activity toward lysoPI, lysoPI4P, or lysoPI(4,5)P~2~ in the membrane fractions of HEK 293A cells transfected with vector control or *Lpiat1* expression plasmid. ND, not detected or present only in trace amounts. Protein at 1 μg was used. Data are means ± SD (*n* = 3).](4689fig3){#F3}

AA metabolites in *Lpiat1*^−/−^ mice
------------------------------------

AA cleaved from phospholipids is converted to bioactive mediators such as prostaglandins and leukotrienes. An LC-MS/MS analysis showed that the amounts of free AA and its metabolites such as prostaglandin D~2~ (PGD~2~) and 5-hydroxyeicosatetraenoic acid (5-HETE) were slightly but not significantly reduced in the *Lpiat1^−/−^* mouse brain compared with the *Lpiat1^+/+^* mouse brain ([Table 1](#T1){ref-type="table"}). Leukotrienes were not detectable under the present conditions.

###### 

AA metabolites of *Lpiat1^+/+^* and *Lpiat1^−/−^* brains.

  AA metabolite    *Lpiat1*^+/+^   *Lpiat1*^−/−^
  ---------------- --------------- ---------------
  AA               1620 ± 307      971 ± 120
  PGE~2~           0.581 ± 0.113   0.482 ± 0.121
  PGD~2~           1.95 ± 0.64     0.873 ± 0.236
  PGF~2α~          0.447 ± 0.094   0.412 ± 0.080
  6-keto-PGF~1α~   1.02 ± 0.14     0.809 ± 0.204
  TXB~2~           3.84 ± 0.94     4.74 ± 0.98
  5-HETE           1.15 ± 0.30     0.424 ± 0.070
  12-HETE          0.165 ± 0.043   0.069 ± 0.030
  15-HETE          0.201 ± 0.052   0.168 ± 0.042

P0 brains were harvested, weighed, and frozen immediately in liquid nitrogen. Data are pg/mg wet weight expressed as means ± SEM (*n* = 6). TXB~2~, thromboxane B~2~.

*Lpiat1*^−/−^ mice show abnormal brain morphology
-------------------------------------------------

Matings between *Lpiat1* heterozygous mice yielded significantly fewer P0 *Lpiat1^−/^*^−^ progeny than expected according to Mendelian inheritance (18.0%; *p* = 0.0027, chi-square test), whereas the genotypes of embryonic day 16.5 (E16.5) and E18.5 progeny followed the expected Mendelian frequencies ([Table 2](#T2){ref-type="table"}). The number of surviving *Lpiat1^−/^*^−^ mice diminished markedly in the 4 wk after birth ([Figure 4A](#F4){ref-type="fig"}). *Lpiat1^−/^*^−^ mice were significantly smaller than *Lpiat1^+/^*^−^ and *Lpiat1^+/^*^+^ littermates ([Figure 4, B and C](#F4){ref-type="fig"}).

![Abnormal morphology of the *Lpiat1^−/^*^−^ brain. (A) Juvenile lethality of *Lpiat1^−/^*^−^ mice (*n* = 14). (B) Representative photograph of *Lpiat1^−/^*^−^ mouse compared with a wild-type littermate at 3 wk of age. Scale bar, 1 cm. (C) Body weights of *Lpiat1*^+/+^, *Lpiat1^+/^*^−^, and *Lpiat1^−/^*^−^ mice at different points in time. Littermates of all genotypes (+/+, *n* = 29; +/−, *n* = 41; −/−, *n* = 14) were weighed at 1 and 2 wk of age. Newborn littermates (+/+, *n* = 6; +/−, *n* = 12; −/−, *n* = 4) were weighed before killing for primary hippocampal culture (see [Figure 9](#F9){ref-type="fig"}). NB, newborn. Data are means ± SEM \**p* \< 0.05; \*\**p* \< 0.01. The analysis of variance with Tukey-Kramer post hoc test was used. (D) Brains from *Lpiat1^+/^*^+^ and *Lpiat1^−/^*^−^ littermates at E18.5. cx, cortex; hb, hindbrain; mb, midbrain; ob, olfactory bulb. Scale bar, 2.5 mm. (E, F) Sagittal sections of the brains from E18.5 *Lpiat1^+/+^* (E) and *Lpiat1^−/^*^−^ (F) littermates were stained with hematoxylin and eosin (H&E). cb, cerebellum; cx, cortex; hi, hippocampus; mb, midbrain; ob, olfactory bulb. The red asterisk indicates the atrophic cortex, and the yellow star indicates the atrophic hippocampus. Scale bar, 500 μm.](4689fig4){#F4}

###### 

Genotypes of litters from *Lpiat1*^+/−^ intercrosses.

                                   *Lpiat1* Genotype                   
  ------------ ------------------- ------------------- ------ -------- -----
  E16.5        Number of animals   28                  52     28       108
               Percentage (%)      26.0                48.1   26.0     100
  E18.5        Number of animals   27                  43     23       93
               Percentage (%)      29.0                46.2   24.7     100
  Birth (P0)   Number of animals   126                 247    82       455
               Percentage (%)      27.7                54.3   18.0\*   100

Neonates and embryos were harvested at the times indicated. Genomic DNA was extracted from the tail of each pup and subjected to PCR analysis to determine the genotype. Only live-born animals are counted at birth (P0). \**p* = 0.0027. The *p* values were calculated using the chi-square test.

At E18.5, the forebrain of *Lpiat1^−/^*^−^ mice was smaller in size, whereas the midbrain appeared to be normal in size ([Figure 4D](#F4){ref-type="fig"}). Histological analysis revealed that the sizes of the cerebral cortex and hippocampus were reduced in the *Lpiat1^−/^*^−^ brain ([Figure 4, E and F](#F4){ref-type="fig"}). The laminar structures of the cerebral cortex and hippocampus were disarranged in the *Lpiat1^−/^*^−^ brain. These results indicate that LPIAT1 deficiency causes atrophy of the cerebral cortex and hippocampus and disordered lamination in the cortical layer.

The mammalian neocortex has a characteristic laminar structure composed of six layers of different cells. The cortical layer formation begins around E10--12 ([@B22]). First, the earliest-born cells from cortical ventricular zone migrate toward the pial surface to form the preplate. Subsequently generated neurons arise from the ventricular zone and migrate into the preplate to form the cortical plate (layer 6), splitting the preplate into the marginal zone (layer 1) and the subplate below. Thereafter, newly born neurons migrate past the subplate and older cortical plate neurons to form more superficial layer, thereby making layers 2--6 in an inside-out pattern by E18.5 ([@B41]; [@B54]). We analyzed the layer formation in *Lpiat1^−/^*^−^ mice with specific markers. Tbr1 is a marker of early-born neurons. At E18.5, Tbr1-positive neurons were located mainly in the lower cortical plate (layer 6; [@B24]) in wild-type mice ([Figure 5A](#F5){ref-type="fig"}), whereas they were broadly scattered throughout the cortical plate in *Lpiat1^−/^*^−^ mice ([Figure 5B](#F5){ref-type="fig"}). Brn1 is a marker of the late precursor cells of the ventricular and subventricular zones and the migrating neurons. By E18.5, Brn1-positive neurons in wild-type mice had migrated into the cortical plate ([Figure 5C](#F5){ref-type="fig"}), as shown previously ([@B34]), whereas most of the Brn1-positive neurons were stacked in the intermediate zone in *Lpiat1^−/^*^−^ mice ([Figure 5D](#F5){ref-type="fig"}). Cells positive for Reelin, a marker of Cajal--Retzius neurons ([@B2]; [@B13], [@B14]; [@B36]), were normally distributed in the marginal zone of the *Lpiat1^−/^*^−^ cortex ([Figure 5, A and B](#F5){ref-type="fig"}). In the wild-type cortex, MAP2-positive neuronal processes were arranged radially and formed a tight, palisade-like structure ([Figure 5E](#F5){ref-type="fig"}). In contrast, in *Lpiat1^−/^*^−^ mice, the palisade-like neuronal processes were disordered in the cortex, and the subplate neurons, which are also stained by MAP2 ([@B32]), were dispersed ([Figure 5F](#F5){ref-type="fig"}). Neuronal differentiation during early corticogenesis at E14.5 appeared normal in *Lpiat1^−/^*^−^ mice as assessed by the expressions of βIII-tubulin, Tbr1, and MAP2 ([Figure 6](#F6){ref-type="fig"}). These data indicate that LPIAT1 is required for normal cortical lamination.

![Abnormal cortical lamination in *Lpiat1^−/−^* mice. Sagittal sections of neocortices from E18.5 *Lpiat1^+/+^* (A, C, E) and *Lpiat1^−/^*^−^ (B, D, F) littermates were stained with antibodies against Reelin and Tbr1, and DNA dye Hoechst 33342 (green, magenta, and blue, respectively; A, B), Brn1 (yellow; C, D), and MAP2 (green; E, F). cp, cortical plate; iz, intermediate zone; mz, maginal zone; sp, subplate. Scale bar, 100 μm.](4689fig5){#F5}

![Loss of LPIAT1 does not affect neuronal differentiation. Coronal sections of the E14.5 neocortices were stained with antibodies against βIII-tubulin, Tbr1, and MAP2. cp, cortical plate; iz, intermediate zone; mz, maginal zone; vz, ventricular zone. Scale bar, 50 μm.](4689fig6){#F6}

Neuronal migration is delayed in *Lpiat1*^−/−^ mice
---------------------------------------------------

The disturbed laminar organization of the *Lpiat1^−/^*^−^ cortex suggested that the migrations of cortical cells were abnormal. We injected pregnant females with 5-bromodeoxyuridine (BrdU) at E15.5, when neurogenesis of the middle and superficial layers is at a peak, and examined the localization of BrdU-positive cortical neurons at E18.5. Most of the BrdU-positive cells were superficially distributed in the *Lpiat1^+/^*^+^ cortex ([Figure 7A](#F7){ref-type="fig"}). In the *Lpiat1^−/^*^−^ cortex, the number of BrdU-positive cells was comparable to that of the *Lpiat1^+/^*^+^ cortex, suggesting that neurogenesis is not affected in *Lpiat1^−/^*^−^ mice at E15.5. However, the proportion of cells in the superficial cortex was significantly reduced in the *Lpiat1^−/^*^−^ cortex ([Figure 7B](#F7){ref-type="fig"}). These results suggest that loss of LPIAT1 leads to a significant delay in neuronal migration. We also found that the number of apoptotic cells increased in the *Lpiat1^−/^*^−^ cortex as judged by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) assays ([Figure 8](#F8){ref-type="fig"}), suggesting that atrophy of the cerebral cortex in *Lpiat1^−/^*^−^ mice is caused by increased apoptosis of neuronal cells.

![Neuronal migration is delayed in *Lpiat1^−/−^* mice. (A) Coronal sections of neocortices from E18.5 *Lpiat1^+/+^* and *Lpiat1^−/^*^−^ littermates labeled with BrdU at E15.5. Scale bar, 50 μm. (B) The radial distribution of BrdU-labeled cells. Data are means ± SEM (*n* = 4). \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Unpaired, two-tailed *t* test was used.](4689fig7){#F7}

![Loss of LPIAT1 causes increased apoptosis in early corticogenesis. Apoptotic cell death in coronal sections was examined by TUNEL staining at E14.5. Scale bar, 100 μm.](4689fig8){#F8}

Neurite outgrowth is reduced in *Lpiat1*^−/−^ hippocampal neurons
-----------------------------------------------------------------

We then examined the role of LPIAT1 in neurite outgrowth of primary hippocampal neurons. Hippocampal neurons obtained from P0 brains were cultured for 72 h and immunostained with a βIII-tubulin antibody to visualize neuronal morphology. Hippocampal neurons from *Lpiat1^−/^*^−^ mice had significantly fewer cells with neurites than did those from *Lpiat1^+/^*^+^ mice ([Figure 9, A and B](#F9){ref-type="fig"}). Moreover, the total neuritic length per cell and the length of the longest neurite in each cell were significantly reduced in *Lpiat1^−/^*^−^ cells ([Figure 9, C and D](#F9){ref-type="fig"}). Taken together, these results indicate that LPIAT1 deficiency causes defects in neuronal migration and neurite outgrowth, leading to cortical and hippocampal malformation.

![LPIAT1 deficiency causes defects in neurite elongation. (A) Cultured hippocampal neurons from P0 brains were stained with neuronal marker anti--βIII-tubulin antibody (green) and 4′,6-diamidino-2-phenylindole (blue) at DIV3. Scale bar, 50 μm. Percentage of cells with neurites (B), total neurite length (C), and longest neurite length (D) of cultured hippocampal neurons from *Lpiat1^+/+^* and *Lpiat1^−/^*^−^ mice. At least 50 neurons were measured for each group. Data are means ± SEM (*n* = 4). \**p* \< 0.05; \*\**p* \< 0.01. Unpaired, two-tailed *t* test was used.](4689fig9){#F9}

DISCUSSION
==========

In this article, we showed that *Lpiat1^−/^*^−^ mice have reduced content of AA in PI and have defects in cortical lamination during brain development. Intensive efforts have been made to understand the physiological roles of AA-derived metabolites such as prostaglandins and leukotrienes. However, little is known about the function of AA when attached to phospholipids other than serving as a source of free AA. Metabolites of AA have been reported to be involved in neuronal functions ([@B58]; [@B10]; [@B47]; [@B7]). As far as we know, mice with knockout of any AA-metabolizing enzyme, such as cPLA~2~α, MAGL, and 5-LOX, or knockout of the receptors for prostaglandins and leuko­trienes, such as PGE~2~ receptors, do not show phenotypes similar to those of *Lpiat1^−/−^* mice ([@B11]; [@B9]; [@B56]; [@B57]). Moreover, the levels of major AA metabolites were not significantly changed in the *Lpiat1^−/−^* brain. Thus the defects in brain development seen in *Lpiat1^−/−^* mice are unlikely caused by the reduction or the impairment of the signaling pathways regulated by AA-derived metabolites.

In addition to PI, AA contents of PIP and PIP~2~ were also reduced in the *Lpiat1^−/^*^−^ brain. Previous in vitro studies demonstrated that whereas lysoPI was acylated with \[^3^H\]AA by the microsomes from rat liver and brain in the presence of ATP, CoA, and Mg^2+^, neither lysoPI4P nor lysoPI(4,5)P~2~ was acylated with \[^3^H\]AA under the same assay conditions ([@B39]). In the present study, we confirmed this observation and also showed that overexpression of LPIAT1 in cultured cells did not increase acyltransferase activity toward lysoPI4P or lysoPI(4,5)P~2~. These results indicate that LPIAT1 does not use lysoPI4P or lysoPI(4,5)P~2~ as an acyl acceptor. Nevertheless, the AA contents of PI phosphates and PI showed similar decreases in the *Lpiat1^−/−^* brain, suggesting that the reduction in the AA content in PI phosphates may result from the reduction of AA content in PI, a precursor of PI phosphates.

PI phosphates are synthesized by PI kinases and phosphatases and play crucial roles in the regulation of a wide variety of cellular processes via specific interactions of PIP-binding proteins ([@B16]; [@B45]). Among PI phosphates, PI 3-phosphate (PI3P) regulates a variety of vesicular trafficking pathways, including endocytosis, endosome-to-Golgi retrograde transport, autophagy, and the target of rapamycin (TOR) signaling pathway ([@B3]). PI3P is synthesized from PI by a class III PI 3-kinase, Vps34 ([@B3]). Recently we showed that knockdown of *vps-34*, a *C. elegans* orthologue of Vps34, causes severe growth defects in *mboa-7* mutants ([@B31]). Moreover, PI3P signaling pathways such as autophagy and endosome morphology were impaired in *mboa-7* mutants. Of interest, [@B63]) recently showed that neuron-specific Vps34 conditional knockout mice exhibit defects in cortical lamination, which is very similar to that of *Lpiat1^−/−^* mice. On the basis of these observations, we hypothesize that reduction of AA content in PI3P impaired PI3P function(s), which leads to cortical lamination defects in *Lpiat1^−/−^* mice. The observation that the fatty acid compositions of PIP and PIP~2~ were changed similarly to that of PI in *Lpiat1^−/−^* mice suggests that the enzymes involved in the synthesis of PIP and PIP~2~ do not prefer AA-containing PI as a substrate. Change in the fatty acid composition in PI phosphates may affect the interaction with PI phosphate--binding proteins and/or the intramembrane localization of PI phosphates in subcellular organelles. We are testing this hypothesis.

∆6-Fatty acid desaturase (FADS2) converts linoleic acid (18:2n-6) to γ-linolenic (18:3n-6), and ∆5-fatty acid desaturase (FADS1) converts dihomo-γ-linolenic acid (20:3n-6) to AA. *Fads2^−/−^* mice show reduced content of PUFAs, including AA in tissues ([@B51]; [@B52]). *Fads2^−/−^* mice exhibit a variety of symptoms, including sterility, ulceration, and dermatitis. PUFA supplementation restores the symptoms in *Fads2^−/−^* mice and in patients with ∆6-desaturase deficiency ([@B51]; [@B52]; [@B42]; [@B59]). *Fads1^−/−^* mice began to die gradually starting at 5--6 wk of age, with no survivors past 12 wk of age, although no overt physical differences between *Fads1^−/−^* and wild-type mice were observed ([@B19]). Thus *Fads1^−/−^* and *Fads2^−/−^* mice did not show any phenotypes similar to those of *Lpiat1^−/−^* mice. Although *Fads1^−/−^* and *Fads2^−/−^* mice are ideal for studying the function of AA and other PUFAs in vivo, PUFAs are supplied from the heterozygous mother through placental transfer in the homozygous embryos. Moreover, the content of PUFAs in the brain tends to remain stable even under PUFA-depleted conditions ([@B20]; [@B52]). *Lpiat1^−/−^* embryos have a defect in the synthesis of AA-containing PI using AA derived from their heterozygous mother. Thus it is plausible that *Fads2^−/−^* mice and *Lpiat1^−/−^* mice show distinct brain phenotypes in the embryonic stage.

The fact that a considerable amount of AA remained in PI of *Lpiat1^−/−^* mice suggests that there are other pathways to enrich AA in PI. Lysophosphatidic acid acyltransferase (LPAAT) may catalyze the incorporation of PUFAs into the *sn*-2 position of lysophosphatidic acid (lysoPA) during de novo phospholipid synthesis. Mammalian LPAATs show relatively broad substrate specificity for acyl-CoAs and incorporate AA into lysoPA ([@B49]; [@B18]). Cytidine 5′-diphosphate-diacylglycerol synthase (CDS) catalyzes the biosynthesis of CDP-diacylglycerol, a direct precursor of PI, from phosphatidic acid (PA). CDS1, an isoform of CDS that is highly expressed in the brain, prefers AA-containing PA as a substrate ([@B43]). Therefore it is possible that PI-containing AA can be synthesized once AA is incorporated into PA via the de novo pathway.

It has been recognized for decades that AA-containing PI is a major molecular species in PI in mammals. By knocking out LPIAT1---the enzyme responsible for incorporation of AA into PI---we showed for the first time that AA-containing PI is essential for brain development in mammals.

MATERIALS AND METHODS
=====================

Materials
---------

\[1-^14^C\]-labeled fatty acids and fatty acyl-CoAs were purchased from American Radiolabeled Chemicals (St. Louis, MO). Arachidonoyl-CoA was obtained from Sigma-Aldrich (St. Louis, MO). LysoPI from bovine liver, lysophosphatidylserine from porcine brain, lysoPE from porcine liver, lysoPC from egg yolk, *sn*-1-oleoyl-lysoPA, PI4P from porcine brain, and PI(4,5)P~2~ from porcine brain were purchased from Avanti Polar Lipids (Alabaster, AL). Dipalmitoyl PI was purchased from Serdary Research Laboratories (London, Canada). PLA~2~ from honey bee venom was purchased from Sigma-Aldrich. AA-d~8~, 15-HETE-d~8~, LTB~4~-d~4~, and PGE~2~-d~4~ were purchased from Cayman Chemical (Ann Arbor, MI).

Animals
-------

Specific pathogen-free female C57BL/6 mice were obtained from CLEA Japan (Tokyo, Japan). We used *Lpiat1*-deficient mice backcrossed eight times to C57BL/6 background. Mice were maintained in our animal facility and treated in accordance with the guidelines of the Institutional Animal Care Committee (Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan).

Generation of LPIAT1-deficient mice
-----------------------------------

E14K murine embryonic stem (ES) cells heterozygous for a deletion mutation of the *Lpiat1* gene were generated. We replaced exons 2--4 of the murine *Lpiat1* gene with a PGK-Neo cassette because the putative translation initiation codons were identified in exons 2--4 but not in exon 1. The targeting vector contained a 5.5-kb genomic murine (129/Ola) *Lpiat1* fragment plus the PGK-Neo cassette inserted in antisense orientation to *Lpiat1* transcription. The linearized construct was electroporated into 1 × 10^7^ E14K ES cells. ES cell colonies resistant to G418 (0.3 mg/ml) were screened for homologous recombination by PCR. Four different targeted ES cells derived from two independent electroporation experiments were injected into C57BL/6 blastocysts. Chimeric male mice were crossed with C57BL/6 females to achieve germline transmission. After heterozygous matings, *Lpiat1*^−/−^ mice were distinguished from *Lpiat1^+/−^* and *Lpiat1*^+/+^ mice by PCR. An oligo primer specific for the *Lpiat1*^+^ allele (P1, 5′-CACGCCCTTCACCAATGCTG-3′), a primer common to the *Lpiat1*^+^ and *Lpiat1*^−^ alleles (P2, 5′-TGGAGGACGGTTTGCTACAGACTC-3′), and a primer specific for the *Lpiat1*^−^ allele (P3, 5′-AGACTGCCTTGGGAAAAGCG-3′), were combined in the same PCR.

Generation of anti-mouse LPIAT1 antibody
----------------------------------------

A recombinant mouse LPIAT1 (amino acids 274--334 of mouse LPIAT1, GenBank accession no. NM_029934.3) that was expressed and purified by an *Escherichia coli* pCold TF expression system (TaKaRa, Otsu, Japan) was injected into the hind foot pads of WKY/Izm rat strain by using Freund\'s complete adjuvant. The enlarged medial iliac lymph nodes were used for cell fusion with mouse myeloma cells, PAI. In the present study, the established monoclonal antibody FT10 was used for immunoblotting and immunohistochemistry at dilutions of 1:1000 and 1:100, respectively.

Western blot analysis
---------------------

Tissues from 2-wk-old mice were homogenized in 9× volume (wt/vol) of SET buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 250 mM sucrose) with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 2 μg/ml aprotinin). After centrifugation at 1000 × *g* at 4°C, the supernatants were used as the total protein extracts. The protein concentrations of samples were determined by the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL). Each total protein extract was separated by SDS--PAGE and transferred to either polyvinylidene difluoride (PVDF) or nitrocellulose membranes. The membranes were blocked with skim milk (Wako Pure Chemical Industries, Osaka, Japan) in TTBS buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% \[wt/vol\] Tween 20) and incubated with the specific monoclonal rat anti-mouse LPIAT1 antibody FT10 (see prior description). After incubation with horseradish peroxidase--conjugated goat anti--rat immunoglobulin G antibody (American Qualex, San Clemente, CA), LPIAT1 was detected by enhanced chemiluminescence (ECL Western blotting detection system; GE Healthcare, Piscataway, NJ). Anti--glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 6C5) was purchased from Calbiochem (La Jolla, CA).

Acyltransferase assay
---------------------

Murine tissues were pulverized under liquid nitrogen and homogenized in quadruple volumes (wt/vol) of SET buffer with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 2 μg/ml aprotinin). After centrifugation at 2330 × *g* for 20 min at 4°C, the resulting supernatant was further centrifuged at 105,000 × *g* for 60 min. The pellet was suspended in homogenizing buffer (without EDTA, phenylmethylsulfonyl fluoride, pepstatin, leupeptin, and aprotinin) and used for the enzyme assay. Acyl-CoA:1-acyl lysophospholipid acyltransferase assay was carried out as described before ([@B26]), except that the incubation temperature was 37°C and that 5 μg ([Figure 1H](#F1){ref-type="fig"}) or 20 μg ([Figure 1I](#F1){ref-type="fig"}) of microsomal protein was used. The protein concentrations of samples were determined by the BCA assay (Pierce).

Acyltransferase assay toward lysoPI phosphates
----------------------------------------------

*sn*-1-acyl lysoPI4P and *sn*-1-acyl lysoPI(4,5)P~2~ were prepared as described previously ([@B39]). P0 brains and HEK 293A cells were homogenized in phosphate buffer (pH 7.0) containing 0.15 M KCl, 0.25 M sucrose, 1 mM EDTA, 1 mM dithiothreitol, and 5 μg/ml pepstatin, leupeptin, and aprotinin (homogenizing buffer). After centrifugations at 1000 × *g* for 5 min and 10,000 × *g* for 30 min at 4°C, the supernatant was collected and centrifuged at 105,000 × *g* for 60 min at 4°C. The resulting pellet was resuspended in homogenizing buffer (without EDTA, dithiothreitol, and protease inhibitors) and used for the enzyme assay to be described. \[^14^C\]arachidonoyl-CoA (53 mCi/mmol) was diluted with the unlabeled arachidonoyl-CoA to 10 mCi/mmol before use. Reaction mixtures contained 10 μM of AA-CoA (10 mCi/mmol) and 10 μM of lysoPI(4,5)P~2~ and 5 μg (for brains) or 1 μg (for cells) of microsomal protein in a total volume of 0.2-ml assay buffer (0.15 M KCl, 0.25 M sucrose, 50 mM potassium phosphate buffer, pH 6.8). After incubation at 37°C for 5 min, reactions were stopped by the addition of 1 ml of methanol. The lipids were extracted as described previously ([@B46]) and separated by one-dimensional TLC on silica gel 60 plates (Merck, Darmstadt, Germany) in chloro-form:methanol:concentrated NH~4~OH:water (45:45:4:11, vol/vol) ([@B55]). Acyltransferase activity toward lysoPI was also performed in the same assay condition to compare the acyl acceptor preference of LPIAT1.

Histological analysis
---------------------

Brains were embedded in paraffin wax, and serial sagittal sections were mounted on slides and stained with hematoxylin and eosin. For immunohistochemistry, brain sections were blocked for 30 min with 2% bovine serum albumin (BSA; Sigma-Aldrich) diluted in phosphate-buffered saline (PBS) containing 0.1% Tween 20 at room temperature and then incubated in primary antibody diluted in 2% BSA-PBS for 2 h. Primary antibodies and their dilutions used in this study were as follows: Reelin (CR50; 1:1000; [@B36]), Tbr1 (AB9616; 1:500; Millipore, Billerica, MA), Brn1 (SC-6028; 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), MAP2 (M1406; 1:1000; Sigma-Aldrich), βIII-tubulin (GT431195; 1:500; Genzyme-Techne, Minneapolis, MN). Sections were incubated with fluorescent secondary antibodies (Alexa series; Molecular Probes, Eugene, OR) diluted at 1:400 in 2% BSA-PBS for 1 h at room temperature. Slides were washed for several hours in PBS and coverslips applied with Dako fluorescent mounting medium (Dako, Glostrup, Denmark). TUNEL analysis was performed using the Apop Tag Plus fluorescein In Situ Apoptosis Detection Kit (Millipore) according to the manufacturer\'s instructions.

BrdU labeling and analysis
--------------------------

For BrdU experiments, pregnant mice were injected with BrdU (50 mg/g, intraperitoneally) at E15.5, and perinatal embryos were removed by cesarean section at E18.5. Embryo heads were fixed in 4% paraformaldehyde, and the brains were dissected out and soaked overnight in 20 and 30% sucrose and equilibrated and embedded in OCT on dry ice. Sections were stored frozen until use. After permeabilization with HCl, BrdU was detected by rat anti-BrdU antibodies (AB6326; 1:150; Abcam, Cambridge, MA). To determine the distribution of cells born at E15.5 in *Lpiat1^+/+^* and *Lpiat1^−/−^* cortex, sections were divided into the horizontal bins from superficial to deep, and the percentage of cells in each bin was calculated.

Primary culture
---------------

The primary culture of neurons was prepared from hippocampi or cerebral cortices of E18.5 or P0 mice as described previously ([@B5]). The dissociated cells were plated on poly-[l]{.smallcaps}-lysine (Sigma-Aldrich)--coated dishes or coverslips and cultured in Neurobasal Medium (for expression analysis of LPIAT1, E18.5) or Neurobasal-A Medium (for morphometric analysis, P0; Invitrogen, Carlsbad, CA) supplemented with 2.5 mM [l]{.smallcaps}-glutamine (Nacalai Tesque, Kyoto, Japan), 2.5% (vol/vol) B-27 (Invitrogen), and antibiotics (250 U/ml penicillin and 250 mg/ml streptomycin). As for morphometric analysis, neurons were cultured at a density of 2.5 × 10^4^ cells/well in 24-well flat-bottom plates and fixed at 3 d in vitro (DIV) and then immunostained with the anti-TUJ1 antibody against the neuronal-specific βIII-tubulin (MAB1195; R&D Systems, Minneapolis, MN) at dilution of 1:5000. Cell images were captured by a fluorescence microscope (FSX100; Olympus, Tokyo, Japan), and then the length of neurites and the neurite number were determined.

Lipid analysis
--------------

Lipids of each tissue were extracted by the method of [@B8]). The fatty acid composition was determined by gas chromatography as described previously ([@B30]), except that the solvent used in the one-dimensional TLC was chloroform:methyl acetate:1-propanol:methanol:0.25% KCl (25:25:25:10:9, vol/vol; [@B26]). LC/ESI-MS analysis was performed as described previously ([@B37]; [@B26]). Lipid phosphorus was determined by Bartlett\'s method ([@B6]).

Cell culture and transfection
-----------------------------

Human embryonic kidney (HEK) 293A cells were maintained in DMEM supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 mg/ml), and [l]{.smallcaps}-glutamine (2 mM). Transfection of the plasmid DNA into cells was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s protocol.

Plasmid construction
--------------------

Full-length mouse *Lpiat1* was amplified by PCR from mouse cDNA with primers Lpiat1 forward (5′-ACGGTTGAATTCATGACACCCGAAGAATGGAC-3′) and reverse (5′-CAGCAGCTCGAGCTCTTCCCGGAGCTTTTCCT-3′) and was cloned into pCAGGS-myc vector (C-terminal Myc tag) at the *Eco*RI and *Xho*I sites.

Metabolite extraction and analysis
----------------------------------

Arachidonic acid metabolites were extracted from P0 mouse brains by solid-phase extraction using Sep-Pak C18 cartridges (Waters, Milford, MA) with deuterium-labeled internal standards (AA-d~8~, 15-HETE-d~8~, LTB~4~-d~4~, and PGE~2~-d~4~). LC-MS/MS--based lipidomic analyses were performed using a HPLC system (Waters UPLC) with a linear ion trap quadrupole mass spectrometer (QTRAP 5500; AB Sciex, Foster City, CA) equipped with an Acquity UPLC BEH C~18~ column (1.0 mm × 150 mm × 1.7 μm; Waters). Samples were eluted with mobile phase composed of water/acetate (100:0.1, vol/vol) and acetonitrile/methanol (4:1, vol/vol) (73:27) for 5 min and ramped to 30:70 after 15 min, to 20:80 after 25 min and held for 8 min, ramped to 0:100 after 35 min, and held for 10 min with flow rates of 50 (0--30 min), 80 (30--33 min), and 100 μl/min (33--45 min). MS/MS analyses were conducted in negative-ion mode, and fatty acid metabolites were identified and quantified by multiple reaction monitoring. Quantitation was performed using calibration curves constructed for each compound, and recoveries were monitored using added deuterated internal standards.

This article was published online ahead of print in MBoC in Press (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E12-09-0673>) on October 24, 2012.
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AA

:   arachidonic acid

AA-CoA

:   arachidonoyl-CoA

FADS1

:   Δ5-fatty acid desaturase

FADS2

:   Δ6-fatty acid desaturase

LPIAT1

:   lysophosphatidylinositol acyltransferase 1

PC

:   phosphatidylcholine

PE

:   phosphatidylethanolamine

PI

:   phosphatidylinositol

PIP

:   PI monophosphate

PI3P

:   PI 3-phosphate

PIP~2~

:   PI bisphosphate

PUFA

:   polyunsaturated fatty acid
